Among the emerging industries that have captured the attention of investors is the cannabis sector. The cannabis industry has experienced remarkable growth, giving rise to a new breed of top cannabis stocks to buy for investments in May.Although the results so far from the cannabis industry have disappointed many investors, I feel that the long-term prospects remain promising. While the initial hype and optimism surrounding the legalization of cannabis may have led to unrealistic expectations, it is importa ...

NASDAQ | TSX: ACBCanada's Leading Medical Cannabis Company Launches Premium Products Redefining Patient CareEDMONTON, AB, May 8, 2024 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) the Canadian based leading global medical cannabis company, is proud to announce the arrival of Aurora branded medical cannabis products to the New Zealand market. This new line of premium dried flowers represents a significant milestone in medical cannabis accessibility in New Zealand, an emerging market poised for ...

Aurora Cannabis Inc. (ACB) shares soared 46% in the last trading session to close at $9.23. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 46.6% gain over the past four weeks.The sharp upsurge in Aurora's shares can be attributed to the DEA's reported decision to reclassify marijuana from Schedule I (reserved for drugs with a high potential for abuse) to Schedule III (reserved for drugs with a moderate to low potential for physi ...

The US is planning to reclassify cannabis as a less dangerous drug in an historic shift that could have a significant impact across the country.The Drug Enforcement Administration's (DEA) proposal would recognise the drug's medical properties and acknowledge it has less potential for abuse than other dangerous substances. However the proposal, which still must be reviewed by the White House, would not legalise cannabis outright for recreational use.Marijuana is currently classified in the US as a "schedule ...

Cannabis stocks soared nearly across the board this afternoon on news that President Joe Biden’s administration is moving to reschedule marijuana as a Schedule III substance, a less severe designation than its prior Schedule I classification. Indeed, acting on a review from the Department of Health and Human Substances, the U.S. Drug Enforcement Administration (DEA) and U.S. Justice Department may recategorize cannabis as early as this week. A move to Schedule III would yield major benefits to both the lega ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Product Launch - MedReleaf Australia has introduced new proprietary dried flower products under the Aurora brand, including Black Jelly, Chemango Kush, Moon Berry, and the relaunch of Vespera [1] - The new products are available in four 10g formats: Aurora Moon Berry T9/C13 Balanced, Aurora Black Jelly T28/C1 Sativa, Aurora Chemango Kush T29/C1 Indica, and Aurora Vespera T1/C17 CBD [1] - The expanded product range aims to provide patients with more choices and high-quality medical cannabis solutions [1] Market Strategy - The new offerings are designed to meet market demand for affordable options without compromising quality, focusing on sustainability and large-scale cultivation [1] - MedReleaf Australia has consolidated its brand focus into three core brands: CraftPlant for premium products, Aurora for innovative and affordable options, and IndiMed for company-funded concessions [2] Company Overview - Aurora Cannabis operates in the medical and consumer cannabis markets across Canada, Europe, Australia, and South America, with a commitment to improving lives through cannabis [3] - MedReleaf Australia, a subsidiary of Aurora, was established in 2016 and is licensed to cultivate and manufacture medical cannabis in Australia and New Zealand [4] - The company is backed by over 50 years of combined pharmaceutical and healthcare expertise and has a strategic partnership with Aurora Cannabis Enterprises [4]

Industry Overview - The global cannabis industry is expected to experience significant growth, with a projected compound annual growth rate of over 20% for the next decade, driven by increasing legalization and medical use [1] - Canadian cannabis stocks have shown impressive performance recently, with several stocks achieving double-digit gains, indicating growing investor confidence in the sector [2] Company Highlights: Aurora Cannabis Inc. - Aurora Cannabis Inc. is recognized for its commitment to quality and innovation, with operations including multiple facilities and research centers across Canada [3] - The company has strategically entered the U.S. market by acquiring Reliva, LLC, a leader in hemp-derived CBD products, which helps Aurora leverage an established distribution network despite federal restrictions on THC products [5] - For Q3 FY2024, Aurora reported consolidated revenue of $64.4 million, up from $61.1 million the previous year, with adjusted gross profit rising to $32.4 million, a 15.7% increase [6][7] - Medical cannabis accounted for 70% of Aurora's consolidated revenue and 86% of adjusted gross profit, with notable sales increases in Australia and Europe [7] - The company reduced its net loss to $25.2 million from $62.4 million the previous year, highlighting effective cost management and operational improvements [8] Company Highlights: Canopy Growth Corporation - Canopy Growth Corporation is a leader in the global cannabis industry, known for producing high-quality cannabis products for both medicinal and recreational use [9] - The company has rapidly expanded its production and retail sites in Canada and strategically established a presence in U.S. states with cannabis-friendly laws [11] - Canopy Growth reported a combined gross margin of 36% for Q3 FY2024, with cannabis gross margins in Canada increasing to 28% from a negative 11% in the previous year [13] - The company's net revenue for the quarter was $79 million, a 7% decrease from the previous year, but cannabis revenue outside of Australia surged by 81% [14] - Canopy Growth achieved a $34 million improvement in free cash flow from ongoing operations, marking a 57% increase, and reported a healthy balance of $186 million in cash and short-term investments [15] Future Outlook - Canadian cannabis companies like Canopy Growth and Aurora Cannabis are well-positioned for future growth, particularly with their expansion efforts into international markets, including the U.S. [16] - The U.S. cannabis industry is expected to expand significantly, presenting lucrative opportunities for Canadian companies operating in the American market [17]

Industry Overview - Cannabis stocks are becoming increasingly profitable, with Canopy Growth (CGC) rising from $2.75 to $11.57 recently, currently at $6 [1] - Public support for cannabis legalization in the U.S. is at 88%, with potential legalization in Florida and Germany's recent legalization possibly influencing Europe [1] Company Analysis: Innovative Industrial Properties (IIPR) - IIPR is currently oversold at $94.23 and has a yield of 7.73% [2] - Recent earnings showed funds from operations (FFO) at $2.07, exceeding expectations, and revenue at $79.2 million, up from $70.5 million year-over-year [3] - The company collected 100% rent in the last quarter, and cannabis rescheduling could enhance cash flow for IIPR tenants [3] Company Analysis: Trulieve Cannabis (TCNNF) - TCNNF is trading at $10.74, with a potential target of $13.75 [5] - If Florida legalizes adult-use cannabis, it could significantly impact Trulieve, with the state's medical marijuana market projected to generate $2 billion annually [5] - Trulieve funded $40 million for the legalization initiative and has increased its retail locations to 192 [5] Company Analysis: Aurora Cannabis (ACB) - ACB has seen a price increase from around $3 to $8.88, currently at $6.46, with potential growth linked to the Florida legalization vote [6] - The company is on track for its strongest fiscal year, with five consecutive quarters of positive adjusted EBITDA and significant international revenue growth [7]

Aurora Cannabis Inc. (ACB) closed the latest trading day at $6.46, indicating a -1.15% change from the previous session's end. This move lagged the S&P 500's daily loss of 0.88%. At the same time, the Dow added 0.56%, and the tech-heavy Nasdaq lost 2.05%.Coming into today, shares of the company had gained 70.18% in the past month. In that same time, the Medical sector lost 6.4%, while the S&P 500 lost 2.57%.The investment community will be closely monitoring the performance of Aurora Cannabis Inc. in its fo ...